Products and traceability
Sourcing is part of the safety question
Readers should ask whether a program uses ibogaine or whole-plant iboga, how it identifies the product, and what quality controls support that identification. These are not interchangeable descriptions. The reference overview of ibogaine distinguishes the alkaloid from the plant context; a provider should be able to state plainly what it administers.
For an ibogaine product, useful questions include whether batch records, chain-of-custody information, and independent laboratory documentation are available. For whole-plant iboga, ask how source, preparation, and consistency are documented. A vague answer about a product being “natural” is not a quality-control process.
Continuity after observation
Follow-up should not be an afterthought
Post-treatment medical follow-up should have a defined plan: what symptoms warrant urgent evaluation, what records are provided, how medication questions are handled, and what continuity options are discussed. The practical questions covered in aftercare and continuity planning can help readers look beyond the immediate retreat stay.
It is also reasonable to ask how a program communicates with an outside clinician when a participant chooses to involve one. This does not mean a retreat can promise outcomes; it means the boundary between on-site observation and later care is made explicit.
Red flags to treat seriously
- No ECG or no explanation of QTc assessment.
- Reliance on unlicensed facilitators for medical decisions.
- No written emergency protocol or unclear hospital transfer arrangement.
- No clear account of product identity, records, or quality controls.